GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (STU:H5O0) » Definitions » 3-Year EPS without NRI Growth Rate

Argent Biopharma (STU:H5O0) 3-Year EPS without NRI Growth Rate : 54.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma 3-Year EPS without NRI Growth Rate?

Argent Biopharma's EPS without NRI for the six months ended in Dec. 2024 was €-0.15.

During the past 3 years, the average EPS without NRI Growth Rate was 54.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -12.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Argent Biopharma was 75.10% per year. The lowest was -204.60% per year. And the median was 15.50% per year.


Competitive Comparison of Argent Biopharma's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argent Biopharma's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's 3-Year EPS without NRI Growth Rate falls into.


;
;

Argent Biopharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Argent Biopharma  (STU:H5O0) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Argent Biopharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma Business Description

Industry
Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.

Argent Biopharma Headlines

No Headlines